← Back to Clinical Trials
Recruiting NCT06628414

NCT06628414 WHITBY: Working Towards Better Healthcare Interventions for Tinnitus: a Brain Stimulation studY

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06628414
Status Recruiting
Phase
Sponsor University of Nottingham
Condition Tinnitus
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-12-01
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
transcranial Direct Current Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-12-01 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Tinnitus - the awareness of sound without any outside source - affects around 15% of people and can cause anxiety and depression. Treatment options are limited and do not address tinnitus directly (e.g., reduce its loudness). To do that, we must change brain activity causing tinnitus. Low-dose electrical stimulation, using a technique called transcranial Direct Current Stimulation (tDCS), is a promising approach. The technique is safe and easy to administer. Several small studies have tested tDCS for tinnitus showing some benefits. To assess whether these benefits will generalise to other patients, we need to conduct a randomised controlled trial - a large, rigorously controlled experiment based on prior agreed procedures. Clinical trials are expensive and time-consuming to run and thus require meticulous pilot work to establish the most effective treatment regimens and the most sensitive measures of treatment outcome. The current study aims to provide such pilot information for a clinical trial of tDCS treatment of tinnitus. Using a total of 40 patients, we will establish how to best to administer tDCS and measure resulting changes in tinnitus perception and associated brain activity. The current study is a crucial first step towards determining whether or not tDCS can effectively treat tinnitus.

Eligibility Criteria

Inclusion Criteria: * Aged 18 or over * Suffering from subjective idiopathic tinnitus * Sufficient understanding of English to be able to provide informed consent * Able to safely undergo tDCS Exclusion Criteria: * Aged under 18 * Not suffering from tinnitus or suffering from objective tinnitus * Insufficient understanding of English to be able to provide informed consent * Unable to safely undergo tDCS as assessed by tDCS Safety Questionnaire * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Contact & Investigator

Central Contact

Magdalena Sereda, PhD

✉ magdalena.sereda@nottingham.ac.uk

📞 00441158232625

Principal Investigator

Magdalena Sereda, PhD

PRINCIPAL INVESTIGATOR

University of Nottingham

Frequently Asked Questions

Who can join the NCT06628414 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Tinnitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06628414 currently recruiting?

Yes, NCT06628414 is actively recruiting participants. Contact the research team at magdalena.sereda@nottingham.ac.uk for enrollment information.

Where is the NCT06628414 trial being conducted?

This trial is being conducted at Nottingham, United Kingdom.

Who is sponsoring the NCT06628414 clinical trial?

NCT06628414 is sponsored by University of Nottingham. The principal investigator is Magdalena Sereda, PhD at University of Nottingham. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology